These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27424423)

  • 1. [BRCA mutations: from Angelina Jolie to specific therapies].
    Lopez VA; Stravodimou A; Unger S; Perey L; Zaman K
    Rev Med Suisse; 2016 May; 12(519):973-4, 976-7. PubMed ID: 27424423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Honing the health message on BRCA mutations.
    Schmidt C
    J Natl Cancer Inst; 2013 Dec; 105(24):1843-4. PubMed ID: 24316597
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada.
    Raphael J; Verma S; Hewitt P; Eisen A
    J Genet Couns; 2016 Dec; 25(6):1309-1316. PubMed ID: 27228984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
    Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
    [No Abstract]   [Full Text] [Related]  

  • 8. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
    De Felice F; Marchetti C; Musella A; Palaia I; Perniola G; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Ann Surg Oncol; 2015 Sep; 22(9):2876-80. PubMed ID: 25808098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
    Francken AB; Schouten PC; Bleiker EM; Linn SC; Rutgers EJ
    Breast; 2013 Oct; 22(5):561-8. PubMed ID: 23972475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.
    Skytte AB; Gerdes AM; Andersen MK; Sunde L; Brøndum-Nielsen K; Waldstrøm M; Kølvraa S; Crüger D
    Clin Genet; 2010 Apr; 77(4):342-9. PubMed ID: 20059483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Angelina effect: immediate reach, grasp, and impact of going public.
    Borzekowski DL; Guan Y; Smith KC; Erby LH; Roter DL
    Genet Med; 2014 Jul; 16(7):516-21. PubMed ID: 24357847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Exploration of the Impact of the 'Angelina Jolie Effect' on the Single State-Wide Familial Cancer Program in Perth, Western Australia.
    Freedman R; Mountain H; Karina D; Schofield L
    J Genet Couns; 2017 Feb; 26(1):52-62. PubMed ID: 27265404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Dedicated Follow-Up Clinic for BRCA Mutation Carriers.
    Yerushalmi R; Rizel S; Zoref D; Sharon E; Eitan R; Sabah G; Grubstein A; Rafson Y; Cohen M; Magen A; Birenboim I; Margel D; Ozlavo R; Sulkes A; Brenner B; Perry S
    Isr Med Assoc J; 2016 Sep; 18(9):549-552. PubMed ID: 28471604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
    Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.